FINWIRES · TerminalLIVE
FINWIRES

SHA:601607

18 stories mentioning SHA:601607Updated 3d ago

Every FINWIRES story that references SHA:601607, newest first.

What's the latest news on SHA:601607?

Asia

Shanghai Pharmaceuticals Subsidiary Gets China Approval for Antibiotic

Shanghai Pharmaceuticals (SHA:601607) subsidiary Shanghai Hefeng Pharmaceutical obtained approval from China's National Medical Products Administration for its lincomycin hydrochloride injection, according to a Friday filing with the Shanghai bourse.The drug is indicated for streptococcus, pneumococcus, and staphylococcus infections in patients allergic to penicillin, the filing said.Hospital purchases of the antibiotic reached 21.7 million yuan in 2025, according to market data cited in the filing.

SHA:601607
Asia

Shanghai Pharmaceuticals Declares Interim Dividend

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) will pay out a cash dividend of 0.10 yuan per share for the first half to holders of its Shanghai-listed A shares, according to a Friday bourse filing in Shanghai.The dividend will be distributed on Sept. 18 to shareholders on record as of Sept. 17.The pharmaceutical company's Hong Kong shares slipped 1% during the morning trade, while its Shanghai shares fell marginally.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Uniti Gets China Drug Registration Nod for Blood Cancer Tablets

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) subsidiary Changzhou Pharmaceutical Factory received drug registration certificates from China's National Medical Products Administration for its ruxolitinib phosphate tablets, according to a Tuesday disclosure to the Shanghai bourse.The drug is indicated for myelofibrosis, a form of blood cancer, and graft-versus-host disease in patients aged 12 years and older with inadequate response to glucocorticoids or other systemic therapies, the filing said.The drug company's shares rose nearly 2% in Hong Kong during the midday break on Tuesday.

HKG:2607SHA:601607
Asia

Shanghai Pharma Posts Lower H1 Attributable Profit; Revenue Up

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) reported 3.5 billion yuan in profit attributable to equity holders for the first half, compared with 4.46 billion yuan a year ago, a Thursday bourse filing showed.EPS moved to 0.95 yuan from 1.20 yuan year over year.For the six months ended June 30, operating revenue was 147.5 billion yuan, versus 141.6 billion yuan previously, the pharmaceutical company said.The company proposed an interim dividend of 1 yuan per 10 shares for the period.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals to Dispose of Pharmaceutical Retail Subsidiary Through Public Listing

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) proposed that its unit, Shanghai Pharmaceutical Holding, dispose of its 51% holdings in subsidiary, Shanghai Shangyao Xinte Dong'an Pharmacy, through public listing, according to a Tuesday disclosure on the Shanghai bourse.The proposed minimum listing price is 178.5 million yuan.Shangyao Xinte sells pharmaceuticals and operates Class III medical devices.After the completion of the transaction, the pharmaceutical company will no longer include Shangyao Xinte in its consolidated financial statements.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Gets China Supplementary Approval for Skin Allergy Injection

Shanghai Pharmaceuticals (SHA:601607) received supplementary drug approval from China's National Medical Products Administration for its promethazine hydrochloride injection, according to a Tuesday disclosure to the Shanghai Stock Exchange.The drug is indicated for skin and mucus membrane allergies, as well as motion sickness, and as an adjunct treatment before and after surgery.

SHA:601607
Asia

Shanghai Pharmaceuticals' Unit Received Registration Certificate for Omeprazole, Sodium Bicarbonate for Oral Suspension

Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Shanghai Shangyao Xinyi Pharmaceutical Factory, received a drug registration certificate from China's National Medical Products Administration for omeprazole and sodium bicarbonate dry suspension (I), according to a Shanghai bourse filing on Tuesday.The drug is used for the treatment of active duodenal ulcers and gastroesophageal reflux disease.The pharmaceutical company invested 5.9 million yuan into the research and development of the drug.The company's Hong Kong shares slipped 1% during the morning trade.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Unit Gets Canada Product Licenses for Three Products

Shanghai Pharmaceuticals (SHA:601607) subsidiary Shanghai Zhonghua has obtained Canadian product licenses from Health Canada's Natural and Non-prescription Health Products Directorate for three Longhu-branded products.The products-Cooling Balm Classic, Cooling Balm Ultra and Roll-on Essential Balm-are mainly used for relieving muscle and joint aches, according to a Friday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.

SHA:601607
Asia

Shanghai Pharmaceuticals Subsidiary Gets China Drug Registration Certificate for High Cholesterol Tablets

Shanghai Pharmaceuticals (SHA:601607) subsidiary Changzhou Pharmaceutical Factory received a drug registration certificate from China's National Medical Products Administration for its rosuvastatin ezetimibe tablets, according to a Friday filing with the Shanghai Stock Exchange.The drug is indicated for high cholesterol or homozygous familial hypercholesterolemia, the company said.Mainland Chinese hospitals have so far purchased 25.7 million yuan worth of the drug in 2025.

SHA:601607
Asia

Shanghai Pharmaceuticals Ends Clinical Trial on Salvianolic Acid A for Injection

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) decided to terminate the clinical trial and development of salvianolic acid A for injection, according to a Shanghai bourse filing on Saturday.The Chinese pharmaceutical company's Hong Kong shares rose 2% during Monday's afternoon trade.The drug was intended for the treatment of angina pectoris associated with coronary heart disease.The company said the decision was made to optimize the allocation of funds on projects with "greater strategic advantages".

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Unit Gets China Clinical Trial Approval for Dry Eye Drug

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received clinical trial approval from China's National Medical Products Administration for its Qingrun Yangmu traditional Chinese drug, according to a Tuesday filing with the Shanghai bourse.Qingrun Yangmu, developed by subsidiary Shanghai Pharmaceuticals Group Institute of Traditional Chinese Medicine, is indicated for dry eye.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Arm to Divest 41% Stake in Subsidiary Through Public Listing

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) subsidiary Shanghai Pharmaceutical Holdings will sell a 41% stake in subsidiary Shanghai Pharmaceutical Yiyao Pharmaceutical (Shanghai) for 329.8 million yuan via a public listing, according to a Saturday filing with the Shanghai bourse.Following the transaction, Shanghai Pharma Holdings' ownership in the unit will drop from 51% to 10% and Shanghai Pharmaceutical Holdings will no longer be part of its financial statements.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Commits 300 Million Yuan in Biomedicine Fund

Shanghai Pharmaceuticals (SHA:601607) committed 300 million yuan to participate in a 2-billion-yuan private equity fund focused on early-stage biomedical innovation.The Shanghai Shangshi Biomedicine Industry Private Fund primarily focuses on assets from investigational new drugs to second-phase clinical trials, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.

SHA:601607
Asia

Shanghai Pharmaceuticals Subsidiary Gets Supplementary Drug Approval for Anti-Organ Rejection Tablets

China's drug regulator granted Shanghai Pharmaceuticals (SHA:601607) subsidiary Shanghai Shangyao Xinyi Pharmaceutical Factory a supplementary approval for azathioprine tablets, according to a Tuesday disclosure to the Shanghai bourse.Azathioprine is used with corticosteroids and other immunosuppressants to prevent organ rejection for transplant patients, according to the filing.

SHA:601607
Asia

Shanghai Pharmaceuticals Gets China Approval for Spasm Drug for Infants

China's drug regulator approved Shanghai Pharmaceuticals' (SHA:601607) vigabatrin oral solution powder, according to a Tuesday filing with the Shanghai bourse.The drug is indicated for spasms in infants and children ranging from 1 month to 2 years of age.

SHA:601607
Asia

Shanghai Pharmaceuticals Gets Nod for Manufacturing of Roxadustat Capsules

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received a drug registration certificate from China's National Medical Products Administration for the manufacturing of Roxadustat capsules, according to a Shanghai bourse filing on Saturday.The pharmaceutical company's Hong Kong shares rose 1% during Monday's afternoon trade.The drug is used for the treatment of anemia caused by chronic kidney disease.

HKG:2607SHA:601607
Asia

Shanghai Pharmaceuticals Gains Thai Approval for Rivaroxaban Tablets

Shanghai Pharmaceuticals (SHA:601607) unit Changzhou Pharma obtained Thai Food and Drug Administration approval for rivaroxaban tablets in 10-milligram, 15-milligram and 20-milligram strengths.The generic drug is used to reduce stroke risk in non-valvular atrial fibrillation patients and treat deep vein thrombosis and pulmonary embolism, according to a Friday filing with the Shanghai bourse.

SHA:601607
Asia

Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.

HKG:2607SHA:601607

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:601607 in your portfolio
WheelAI
WheelAI
Analyze SHA:601607 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:601607